• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts

    6/26/25 8:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNY alert in real time by email
    • New fund supports nonprofit partners working to address social drivers of health and strengthen community well-being

    CAMBRIDGE, Mass., June 26, 2025 /PRNewswire/ -- Sanofi today announced it has awarded over $1 million in grants through its inaugural Healthy Futures Solution Fund to support local nonprofits across Massachusetts that are advancing community-led solutions to improve health and well-being in historically undersupported communities. The initiative is part of Sanofi's broader commitment to improve equitable access to healthcare by addressing structural factors, such as lack of access to housing, food, and behavioral health.

    Launched earlier this year, the Fund strategically invests in nonprofit partners with deep roots in the communities they serve. Selected from Sanofi's existing network of Massachusetts-based partners, the grantees will use the funding over the next year to scale programs that address root causes of health disparities while delivering measurable impact for historically undersupported populations.

    Deborah Glasser

    Head, Specialty Care North America and US Country Lead, Sanofi

    "Sanofi believes that the most sustainable health solutions are created by and for the communities closest to the challenges. Through the Healthy Futures Solution Fund, we are honored to support local organizations that possess deep knowledge, lived experience, and trusted relationships at the community level. By investing in their work, we're helping to accelerate progress toward stronger and more equitable health outcomes for all."

    The inaugural grantees of the Healthy Futures Solution Fund are:

    • Boston Health Care for the Homeless - Improving Chronic Disease Management Amongst Homeless Patients
    • Boston Children's Hospital Trust - Sustainable Strategy to Ensure Under-Supported Pediatric Patients Get Access to Care
    • Community Servings - Food is Medicine: Medically Tailored Nutrition Program
    • Family Promise Metrowest – LIFE Family Empowerment Program
    • Fenway Community Health Center - Building Relationships for Inclusive Development and Growth Exchange (BRIDGE) Program
    • Healthy Waltham – Food Pantry & New Community Market
    • Hope & Comfort – Access to Hygiene Products
    • Hospitality Homes – Non-Hosted Medical Lodging for Patients and Families Travelling to Boston
    • International Institute of New England – Boston Refuge and Immigrant Health Equity Initiative
    • Patient Airlift Services – Free Medical Flights for Needy Patients
    • President & Fellows of Harvard College – Wheels of Wellness: The Family Van
    • Saint Francis House – Day Shelter Services
    • St. Mary's Center for Women and Children - Advancing Sustainable Health Equity through Wraparound Support Services Across the Housing Continuum for Women and Children

    Stan McLaren, MBA

    Chief Executive Officer, Boston Health Care for the Homeless Program

    "This funding is an investment in the dignity and well-being of the people we serve. With Sanofi's support, we're able to expand access to integrated care for individuals experiencing homelessness — meeting them where they are and helping address both medical needs and social factors that impact their health."

    The funding period runs through June 2026. At the end of the program, each organization plans to submit an impact report outlining measurable outcomes, learnings, and stories about how the grant affected their community.

    About Sanofi

    Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

    Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

    Media Relations

    Sandrine Guendoul | + 33 6 25 09 14 25 | [email protected]

    Evan Berland | +1 215 432 0234 | [email protected]

    Léo Le Bourhis | + 33 6 75 06 43 81 | [email protected]

    Victor Rouault | + 33 6 70 93 71 40 | [email protected]

    Timothy Gilbert | + 1 516 521 2929 | [email protected]

    Léa Ubaldi | +33 6 30 19 66 46 | [email protected]

    Investor Relations

    Thomas Kudsk Larsen | + 44 7545 513 693 | [email protected]  

    Alizé Kaisserian | + 33 6 47 04 12 11 | [email protected]

    Felix Lauscher | + 1 908 612 7239 | [email protected]  

    Keita Browne | + 1 781 249 1766 | [email protected]

    Nathalie Pham | + 33 7 85 93 30 17 | [email protected]

    Tarik Elgoutni | + 1 617 710 3587 | [email protected]  

    Thibaud Châtelet | + 33 6 80 80 89 90 | [email protected]

    Yun Li | +33 6 84 00 90 72 | [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/sanofi-awards-healthy-futures-solution-fund-grants-to-advance-community-led-solutions-expand-equitable-access-to-care-across-massachusetts-302491030.html

    SOURCE Sanofi

    Get the next $SNY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNY

    DatePrice TargetRatingAnalyst
    9/8/2025$58.00Equal-Weight → Overweight
    Morgan Stanley
    9/2/2025Hold → Buy
    Deutsche Bank
    8/8/2025Neutral → Overweight
    Analyst
    4/15/2025$65.00Outperform
    Exane BNP Paribas
    3/21/2025$65.00Neutral
    Goldman
    1/30/2025Sell → Hold
    Deutsche Bank
    7/26/2024$55.00 → $60.00Buy
    Argus
    1/23/2024$55.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sanofi upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Sanofi from Equal-Weight to Overweight and set a new price target of $58.00

    9/8/25 8:38:18 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi upgraded by Deutsche Bank

    Deutsche Bank upgraded Sanofi from Hold to Buy

    9/2/25 8:23:14 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi upgraded by Analyst

    Analyst upgraded Sanofi from Neutral to Overweight

    8/8/25 7:58:21 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

    For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

    3/28/25 10:17:55 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

    For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

    2/14/25 3:00:13 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

    Submission status for SANOFI-AVENTIS US's drug SOLIQUA 100/33 (SUPPL-14) with active ingredient INSULIN GLARGINE; LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208673, Application Classification:

    11/4/24 4:49:34 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    SEC Filings

    View All

    SEC Form 6-K filed by Sanofi

    6-K - Sanofi (0001121404) (Filer)

    9/26/25 9:41:22 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Sanofi

    6-K - Sanofi (0001121404) (Filer)

    9/22/25 2:59:02 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Sanofi

    6-K - Sanofi (0001121404) (Filer)

    9/17/25 12:03:12 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $SNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

    Initiative spans an IVD assay and a new Revvity Omics lab-developed test to expand clinical testing for early-stage disease screening Revvity, Inc. (NYSE:RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (NASDAQ:SNY). Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay. T1D is a lifelong, progressive autoimmune condition that occurs when the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Early detection of T1D enables options for patients and caregivers to improve outcome

    10/2/25 8:00:00 AM ET
    $RVTY
    $SNY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US

    MORRISTOWN, N.J., Sept. 26, 2025 /PRNewswire/ -- Sanofi US today announces a broad expansion of its Insulins Valyou Savings Program by offering a 30-day supply of any Sanofi insulin for $35 to all patients in the US with a valid prescription. The program, first created for people without health insurance, will be available to all Americans regardless of insurance status, including those with commercial insurance or Medicare, to ensure affordable access to these critical medicines. Sanofi's expanded Insulins Valyou Savings Program now ensures no American needs to pay more than $35 per month for their Sanofi insulins. "Our announcement builds on an idea first championed by President Trump to

    9/26/25 8:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®

    Mandy Moore joins Elaine Welteroth, Gaby Dalkin, Katya Echazarreta, and Shawn Johnson East to share their personal respiratory syncytial virus (RSV) stories and why they chose BEYFORTUS to help protect their babies from serious RSV lung infectionThey join the millions of parents in the US who have chosen BEYFORTUS to help protect their babies from RSV, the number one reason babies under 1 are hospitalizedMORRISTOWN, N.J., Sept. 10, 2025 /PRNewswire/ -- Sanofi is partnering with celebrity moms who chose to immunize their babies with BEYFORTUS® (nirsevimab-alip) to help educate families about the importance of RSV infant protection. BEYFORTUS is the first long-acting monoclonal antibody approv

    9/10/25 8:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Sanofi converted options into 3,088,502 units of Common Stock and bought $1,000,005 worth of Common Stock (66,667 units at $15.00)

    4 - Sanofi (0001121404) (Reporting)

    8/2/21 8:34:24 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Sanofi

    3 - Sanofi (0001121404) (Reporting)

    7/28/21 8:32:04 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    Leadership Updates

    Live Leadership Updates

    View All

    Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care

    TORONTO, June 9, 2025 /CNW/ - Sanofi Canada today announced the appointment of James Guy as Country Lead, Canada and General Manager, Specialty Care. In this role, Guy will lead Sanofi's Canada Country Council, which manages the operations of the company's three business units and functions. Guy will also head the Specialty Care business unit in Canada. James Guy Country Lead, Canada and General Manager, Specialty Care "This is an exciting time in Sanofi's history, with the potential for our promising pipeline to deliver several scientific breakthroughs that can improve healt

    6/9/25 10:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

    ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

    6/6/24 7:00:00 AM ET
    $AZN
    $IMAB
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi Bridging the Gap between the Homeless and Society via Futsal

    Sanofi hosted the founding ceremony of the homeless futsal club ‘Dream' and organized a friendly match as a part of the Helping Hands program Sanofi employees and ‘Dream' members interacted through the friendly match Sanofi has carried out social responsibility activities targeting the homeless and housing vulnerable groups since 2011 Sanofi in Korea[1], the Korean subsidiaries of the global healthcare company Sanofi, hosted the founding ceremony of the homeless futsal club ‘Dream' together with Dalpengyee, a nonprofit organization, to promote self-sufficiency among the homeless. At the founding ceremony of the ‘Dream', held in Seongsu-dong, Seoul on the 17th, the club's first game

    10/17/23 9:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sanofi

    SC 13G/A - Sanofi (0001121404) (Subject)

    11/7/24 2:49:36 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Sanofi

    SC 13G - Sanofi (0001121404) (Filed by)

    5/31/24 4:30:55 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Sanofi (Amendment)

    SC 13G/A - Sanofi (0001121404) (Subject)

    2/14/24 3:57:49 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    Financials

    Live finance-specific insights

    View All

    Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

    Initiative spans an IVD assay and a new Revvity Omics lab-developed test to expand clinical testing for early-stage disease screening Revvity, Inc. (NYSE:RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (NASDAQ:SNY). Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay. T1D is a lifelong, progressive autoimmune condition that occurs when the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Early detection of T1D enables options for patients and caregivers to improve outcome

    10/2/25 8:00:00 AM ET
    $RVTY
    $SNY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

    Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolioPARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU

    6/2/25 1:25:00 AM ET
    $BPMC
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

    - Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for

    5/21/25 7:30:46 PM ET
    $SNY
    $VIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)